Mitochondrial membrane permeabilisation by amyloid aggregates and protection by polyphenols

Biochim Biophys Acta. 2013 Nov;1828(11):2532-43. doi: 10.1016/j.bbamem.2013.06.026. Epub 2013 Jun 28.

Abstract

Alzheimer's disease and Parkinson's disease are neurodegenerative disorders characterised by the misfolding of proteins into soluble prefibrillar aggregates. These aggregate complexes disrupt mitochondrial function, initiating a pathophysiological cascade leading to synaptic and neuronal degeneration. In order to explore the interaction of amyloid aggregates with mitochondrial membranes, we made use of two in vitro model systems, namely: (i) lipid vesicles with defined membrane compositions that mimic those of mitochondrial membranes, and (ii) respiring mitochondria isolated from neuronal SH-SY5Y cells. External application of soluble prefibrillar forms, but not monomers, of amyloid-beta (Aβ42 peptide), wild-type α-synuclein (α-syn), mutant α-syn (A30P and A53T) and tau-441 proteins induced a robust permeabilisation of mitochondrial-like vesicles, and triggered cytochrome c release (CCR) from isolated mitochondrial organelles. Importantly, the effect on mitochondria was shown to be dependent upon cardiolipin, an anionic phospholipid unique to mitochondria and a well-known key player in mitochondrial apoptosis. Pharmacological modulators of mitochondrial ion channels failed to inhibit CCR. Thus, we propose a generic mechanism of thrilling mitochondria in which soluble amyloid aggregates have the intrinsic capacity to permeabilise mitochondrial membranes, without the need of any other protein. Finally, six small-molecule compounds and black tea extract were tested for their ability to inhibit permeation of mitochondrial membranes by Aβ42, α-syn and tau aggregate complexes. We found that black tea extract and rosmarinic acid were the most potent mito-protectants, and may thus represent important drug leads to alleviate mitochondrial dysfunction in neurodegenerative diseases.

Keywords: AD; Alpha-synuclein; Alzheimer's disease; Amyloid-beta; Aβ(42); CCR; CL; Cardiolipin; Cyto c; IM and IMM; Mitochondrial membrane; OGB-1; OM and OMM; Oregon Green® 488 BAPTA-1; PD; Parkinson's disease; Polyphenol; TX-100; Tau; Triton X-100; WT; amyloid-beta (1–42); cardiolipin; cytochrome c; cytochrome c release; inner mitochondrial membrane; outer mitochondrial membrane; wild-type; α-syn; α-synuclein.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyloid beta-Peptides / metabolism*
  • Cell Line, Tumor
  • Humans
  • Mitochondrial Membranes / drug effects
  • Mitochondrial Membranes / metabolism*
  • Permeability
  • Polyphenols / pharmacology*
  • Recombinant Proteins / metabolism
  • alpha-Synuclein / metabolism
  • tau Proteins / metabolism

Substances

  • Amyloid beta-Peptides
  • Polyphenols
  • Recombinant Proteins
  • alpha-Synuclein
  • tau Proteins